Transcription of prostanoid receptor genes and cyclooxygenase enzyme genes in cultivated human iridial melanocytes from eyes of different colours

Pigment Cell Research

Volumn 16, Issue 1, 2003, Pages 43-49

  Wentzel, Parri ^a   Bergh, Kerstin ^a   Wallin, Örjan ^b   Niemelä, Pekka ^a   Stjernschantz, Johan ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b ST ERIK S EYE HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cyclooxygenase; Gene transcription; Iridial melanocytes; Prostaglandin induced melanogenesis; Prostanoid receptors

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LATANOPROST; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR;

ADULT; AGED; ARTICLE; CELL ISOLATION; EYE COLOR; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IRIS; MALE; MELANOCYTE; PIGMENT DISORDER; PIGMENTATION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRABECULECTOMY;

AGED; AGED, 80 AND OVER; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EYE COLOR; FEMALE; HUMANS; IRIS; ISOENZYMES; MALE; MELANOCYTES; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; TRANSCRIPTION, GENETIC;

CORYLUS AMERICANA; EUKARYOTA;

EID: 0037906583     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0749.2003.00001.x     Document Type: Article

References (25)

1. Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-1752
2. Camras CB, The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology 1996;103:138-147
3. Watson P, Stjernschantz J, The Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-137
4. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997;6:430-432
5. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and timecourse of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41 (Suppl. 2):S129-S138
6. Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-422
7. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini HVW, Robertson SM, Davies AA. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484
8. Sherwood M, Brandt J for the Bimatoprost Study Group. Six-month comparison of bimatoprost once-daily and twice-daily with timolol in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45 (Suppl. 4):361-368
9. Stjernschantz JW, Albert DM, Hu D-N, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002;47 (Suppl. 1):S162-S175
10. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41 (Suppl. 2):S125-S128
11. Lenart TD, Drack AV, Tarnuzzer RW, Fernandes A, Lambert SR. Heterochromia after pediatric cataract surgery. J AAPOS 2000;4:40-45
12. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res 1999;69:431-436
13. Prota G, Vincensi MR, Napolitano A, Selén G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res 2000;13:147-150
14. 2α-isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor lecture. Invest Ophthalmol Vis Sci 2001;42:1134-1145
15. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-229
16. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, functions. Physiol Rev 1999;79:1193-1226
17. 2a analogue. J Ocular Pharmacol Ther 2002;18:391-400
18. Hu DN, McCormick SA, Orlow SJ, Rosemblat S, Lin AY. Regulation of melanogenesis by human uveal melanocytcs in vitro. Exp Eye Res 1997;64:397-404
19. Ocklind A, Lake S, Wentzel P, Nister M, Stjernschantz J. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 1996;37:716-726
20. Hellberg MR, Sallee VL, McLaughlin MA, Sharif NA, Desantis L, Dean TR, Zinke PW. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17:421-432
21. Hu DN, McCormick SA, Woodward DF. A functional study on prostanoid receptors involved in cultured human iridal melanocyte stimulation. Exp Eye Res 2001;73:93-100
22. Hu DN, Stjernschantz J, McCormick SA. Effect of prostaglandins A (2), E (1), F (2 alpha) and latanoprost on cultured human iridal melanocytes. Exp Eye Res 2000;70:113-120
23. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001;45 (Suppl. 4):S337-S345
24. Damm J, Rau T, Maihofner C, Pahl A, Brune K. Constitutive expression and localization of Cox-1 and Cox-2 in rabbit iris and ciliary body. Exp Eye Res 2001;72:611-621
25. 2 receptors. Proc Natl Acad Sci 1998;95:15 792-15 797